To advance research for precision oncology, it is essential to identify molecular changes that underly tumorigenesis.

Now you can tailor tumor genomic profiling assays by customizing next-generation sequencing (NGS) cancer panels to fit your laboratory’s specific requirements, including the assessment of new and emerging biomarkers, the immuno-oncology biomarkers (tumor mutational burden (TMB) and microsatellite instability (MSI)), and homologous recombination deficiency (HRD).

Agilent SureDesign, a user-friendly panel design software powered by machine learning, offers fast and easy design of Agilent SureSelect Cancer Custom panels to enable detection of key classes of somatic alterations.

In this webinar, you will learn about:

The range of available tumor genomic profiling assays (comprehensive, tumor-specific, customized) in the Agilent SureSelect Cancer product portfolio
Designing customized cancer panels with SureDesign, by leveraging globally curated, cancer-specific genes and curating your own gene list
Achieving high-quality results from samples such as formalin-fixed, paraffin-embedded (FFPE) tissues
Improving lab efficiency by streamlining library preparation and target enrichment with automation, reducing hands-on time to as little as 15 minutes
Integrated workflows incorporating NGS sample and library QC, compatibility across multiple sequencing platforms, and informatics options

Michael Ruvolo Ph.D.

Director, R&D, Agilent Technologies

Appearances